Josep-Maria Ribera, MD, PhD from Germans Trias i Pujol University Hospital, Barcelona, Spain outlines his talk on minimal residual disease (MRD) and how MRD is assessed by different European groups treating adults with acute lymphoblastic leukemia (ALL). The talk confirmed the crucial role of MRD and highlighted the importance of standardization of MRD methods. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
EHA 2016: The importance of minimal residual disease
